Hangzhou Biotest Biotech Co.,Ltd. (688767.SS)

CNY 32.67

(0.28%)

Market Cap (In CNY)

3.41 Billion

Revenue (In CNY)

442.11 Million

Net Income (In CNY)

106.6 Million

Avg. Volume

431.45 Thousand

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
22.23-35.11
PE
-
EPS
-
Beta Value
0.516
ISIN
CNE1000050H0
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Shujiang Wu
Employee Count
-
Website
https://www.biotests.com.cn
Ipo Date
2021-09-08
Details
Hangzhou Biotest Biotech Co., LTD. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and equipment in China and Internationally. It offers medical test products for fertility health, oncology, cardiology, inflammation, biochemistry, and various infectious diseases, as well as COVID-19 rapid tests, such as antibody and antigen testing kits; and urine and saliva drug, hair drug, and vitamin D rapid testing kits. The company also provides immunochromatography readers and fluorescence immunoassay quantitative analyzers. Hangzhou Biotest Biotech Co., LTD. was founded in 2008 and is based in Hangzhou, China.